<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2022.882651</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Mechanism of COVID-19-Related Proteins in Spinal Tuberculosis: Immune Dysregulation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Liyi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn004">
<sup>&#x2021;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Chong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn004">
<sup>&#x2021;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1356435"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liang</surname>
<given-names>Tuo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/941179"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Zhen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Shengsheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Jiarui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Xuhua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yi</surname>
<given-names>Ming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Chenxing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Jie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Tianyou</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1284315"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Hao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Wuhua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Hao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Wenkang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1610133"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yao</surname>
<given-names>Yuanlin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liao</surname>
<given-names>Shian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1284541"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Chaojie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1280266"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Shaofeng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fan</surname>
<given-names>Binguang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gan</surname>
<given-names>Zhaoping</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhan</surname>
<given-names>Xinli</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1016261"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Spine and Osteopathy Ward, Guangxi Medical University First Affiliated Hospital</institution>, <addr-line>Nanning</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Hematology, Guangxi Medical University First Affiliated Hospital</institution>, <addr-line>Nanning</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Antonio Giovanni Solimando, University of Bari Aldo Moro, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Fabrizio Pappagallo, University of Bari Aldo Moro, Italy; Antonella Argentiero, National Cancer Institute Foundation (IRCCS), Italy </p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Zhaoping Gan, <email xlink:href="mailto:3045275202@qq.com">3045275202@qq.com</email>; Xinli Zhan, <email xlink:href="mailto:Zhanxinli@stu.gxmu.edu.cn">Zhanxinli@stu.gxmu.edu.cn</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other" id="fn004">
<p>&#x2021;These authors share first authorship</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>882651</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Chen, Liu, Liang, Ye, Huang, Chen, Sun, Yi, Zhou, Jiang, Chen, Li, Chen, Guo, Chen, Yao, Liao, Yu, Wu, Fan, Gan and Zhan</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Chen, Liu, Liang, Ye, Huang, Chen, Sun, Yi, Zhou, Jiang, Chen, Li, Chen, Guo, Chen, Yao, Liao, Yu, Wu, Fan, Gan and Zhan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Purpose</title>
<p>The purpose of this article was to investigate the mechanism of immune dysregulation of COVID-19-related proteins in spinal tuberculosis (STB).</p>
</sec>
<sec>
<title>Methods</title>
<p>Clinical data were collected to construct a nomogram model. C-index, calibration curve, ROC curve, and DCA curve were used to assess the predictive ability and accuracy of the model. Additionally, 10 intervertebral disc samples were collected for protein identification. Bioinformatics was used to analyze differentially expressed proteins (DEPs), including immune cells analysis, Gene Ontology (GO) and KEGG pathway enrichment analysis, and protein-protein interaction networks (PPI).</p>
</sec>
<sec>
<title>Results</title>
<p>The nomogram predicted risk of STB ranging from 0.01 to 0.994. The C-index and AUC in the training set were 0.872 and 0.862, respectively. The results in the external validation set were consistent with the training set. Immune cells scores indicated that B cells naive in STB tissues were significantly lower than non-TB spinal tissues. Hub proteins were calculated by Degree, Closeness, and MCC methods. The main KEGG pathway included Coronavirus disease-COVID-19. There were 9 key proteins in the intersection of COVID-19-related proteins and hub proteins. There was a negative correlation between B cells naive and RPL19. COVID-19-related proteins were associated with immune genes.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Lymphocytes were predictive factors for the diagnosis of STB. Immune cells showed low expression in STB. Nine COVID-19-related proteins were involved in STB mechanisms. These nine key proteins may suppress the immune mechanism of STB by regulating the expression of immune genes.</p>
</sec>
</abstract>
<kwd-group>
<kwd>spinal tuberculosis</kwd>
<kwd>COVID-19</kwd>
<kwd>nomogram</kwd>
<kwd>immune cell</kwd>
<kwd>KEGG pathway</kwd>
</kwd-group>    <contract-num rid="cn001">81560359, 81860393</contract-num>    <contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<counts>
<fig-count count="12"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="48"/>
<page-count count="15"/>
<word-count count="6478"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>TB spreads all over the world, with high morbidity and mortality, causing a huge economic burden to society (<xref ref-type="bibr" rid="B1">1</xref>). STB is the most common form of extrapulmonary TB. Typical clinical symptoms of STB include back pain, fever, night sweats, fatigue, weight loss and other symptoms of TB poisoning (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). In addition, STB is often accompanied by complications, including spinal instability, abscesses, spinal deformity and neurologic deficits (<xref ref-type="bibr" rid="B4">4</xref>). TB lesions destroy the vertebral bodies, intervertebral discs, and affect the height of the intervertebral space. In severe cases, the lesions compress the spinal cord and nerves, and surgery is required to relieve the problem. However, after decades even hundreds of years of efforts by scientists, the mechanism of Mycobacterium TB (M. TB)-induced destruction of intervertebral discs in STB has not been clarified.</p>
<p>Macrophages provided a site for M. TB to replicate and exhibited pro- and anti-inflammatory responses during early bacterial clearance (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Bacteria-induced release of tumor necrosis factor (TNF) caused programmed death of pathogenic macrophages through a mitochondrial-lysosomal-endoplasmic reticulum circuit (<xref ref-type="bibr" rid="B7">7</xref>). The function of M. TB in macrophages was inseparable from the regulation of immune cells, which were divided into T lymphocytes and B lymphocytes. B cells first appeared abnormal in active pulmonary TB but returned to normal after the control of M. TB (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). The rapid accumulation of innate lymphoid cells in the lungs following M. TB infection was consistent with the accumulation of alveolar macrophages (<xref ref-type="bibr" rid="B10">10</xref>). Although the function of immune cells in M. TB infection of pulmonary TB was more reported, the role of immune cells in TB intervertebral disc tissue was less reported.</p>
<p>Since the outbreak of coronavirus disease 2019 (COVID-19) in 2019, it had rapidly spread to countries around the world, causing huge economic burdens to countries and societies (<xref ref-type="bibr" rid="B11">11</xref>). With the advancement of scientific research, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was found to be the culprit of the COVID-19 pandemic (<xref ref-type="bibr" rid="B12">12</xref>). Further research found that PGLYRP4 and HEPHL1 were also identified, which were novel transcriptional signature genes associated with SARS-CoV-2 virus (<xref ref-type="bibr" rid="B13">13</xref>). Pulmonary and extrapulmonary TB had been reported in COVID-19 patients with TB, with the former accounting for 73% (<xref ref-type="bibr" rid="B14">14</xref>). Isolated extrapulmonary TB in COVID-19 patients had been reported to occur in various locations, including bone, spinal in location, lymph node, genetourinary, larynx, gastrointestinal, CNS, and peritoneal (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). The study by Rebecca et&#xa0;al. showed 333 fewer TB cases were notified between April 2020 and December 2020, compared to what would have been expected in the absence of the COVID-19 epidemic (<xref ref-type="bibr" rid="B17">17</xref>). Currently, 80 patients co-infected with TB and COVID-19 had been reported from 9 different countries (<xref ref-type="bibr" rid="B14">14</xref>). The results of Tadolini et&#xa0;al. showed that TB patients with COVID 19 had similar predisposing factors to those without COVID 19, including alcohol abuse, COPD, diabetes, liver disease, smoking, HIV and renal failure (<xref ref-type="bibr" rid="B15">15</xref>). However, is TB itself a predisposing factor for COVID 19? Or is the gene or protein of TB associated with COVID 19? Further research is required.</p>
<p>In this article, we analyzed the predictive role of immune cells in STB by collecting clinical data. In addition, we performed bioinformatics analysis of DEPs to explore the association of key proteins in the Coronavirus disease-COVID-19 KEGG pathway and immune mechanism in STB.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>2 Materials and Methods</title>
<sec id="s2_1">
<title>2.1 Patients and Data Collection</title>
<p>Clinical data of 600 patients in the training set were collected from June 2012 to March 2021. Additionally, clinical data of 400 patients were collected as an external validation set from June 2012 to December 2021. A total of 1000 clinical cases were collected from our hospital electronic case database, including 496 STB cases (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) and 504 non-TB spinal cases. The diagnosis of STB relied on pathological examination (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). General patient information was collected, including gender, age, and body mass index (BMI). Patient blood test results were collected, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white blood cells, hemoglobin, platelets, neutrophils, the percentage of neutrophils, lymphocytes, the percentage of lymphocytes, monocytes, and the percentage of monocytes. This project obtained the written consent of all patients and was approved by the hospital ethics committee.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>
<bold>(A, B)</bold> X-ray examination of a patient with spinal tuberculosis. The arrow points to the location of the lesion. <bold>(A)</bold> X-ray image in posterior-anterior position. <bold>(B)</bold> X-ray image in lateral position. <bold>(C&#x2013;E)</bold> CT examination of a patient with spinal tuberculosis. The arrow points to the location of the lesion. <bold>(C)</bold> CT image in sagittal position. <bold>(D)</bold> CT image in coronal position. <bold>(E)</bold> CT image in cross-section. <bold>(F&#x2013;J)</bold> MRI examination of a patient with spinal tuberculosis. The arrow points to the location of the abscess. <bold>(F)</bold> MRI image in the sagittal T1 sequence. <bold>(G)</bold> MRI image in the sagittal T2 sequence. <bold>(H)</bold> MRI image of T2 lipid compression sequence in sagittal position. <bold>(I)</bold> MRI image in coronal position. <bold>(J)</bold> MRI image in cross-section.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g001.tif"/>
</fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Pathological examination of a patient with spinal tuberculosis. Tuberculosis granulomas were observed in tissue sections under a microscope and consisted mainly of dermoid cells, multinucleated giant cells, and lymphocytes. The arrow points to the tuberculosis granulomas and the Langerhans multinucleated giant cells.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g002.tif"/>
</fig>
</sec>
<sec id="s2_2">
<title>2.2 Samples Collection</title>
<p>Ten intervertebral disc nucleus pulposus tissues were collected, including 5 cases of STB nucleus pulposus and 5 cases of non-STB nucleus pulposus. All tissues were cleaned up with phosphate-buffered solution (PBS, Solarbio, Beijing, China) immediately after removal during surgery. The tissues were then placed in liquid nitrogen and transferred to a -80&#xb0;C freezer for storage. Clinical data of 10 patients were also collected, including the Japanese Orthopaedic Association Scores (JOA) score, Oswestry Disability Index (ODI) score, and VAS score.</p>
</sec>
<sec id="s2_3">
<title>2.3 Protein Experimental Procedures</title>
<sec id="s2_3_1">
<title>2.3.1 Protein Extraction</title>
<p>The tissue working solution was mixed and placed on ice to cool. The working solution was PMSF (Phenylmethylsulfonyl fluoride) (Sigma-Aldrich, St.Louis, MO, USA), RIPA lysis buffer (modified, Kangchen Biotech, Shanghai, China), mixed with Protease inhibitor cocktail (Kangchen Biotech, Shanghai, China). Take 1000ul working solution into a 1.5mL EP centrifuge tube, and then add 100mg nucleus pulposus tissue. The nucleus pulposus tissue was fully lysed using ice bath sonication. The EP tube was centrifuged for 15 minutes in a high-speed centrifuge with a speed of 14,000 g at 4&#xb0;C. The centrifuged supernatant was transferred to a new EP tube.</p>
</sec>
<sec id="s2_3_2">
<title>2.3.2 Protein Concentration</title>
<p>Standard protein solutions of 5 gradient concentrations were prepared. The BCA working solution was prepared according to the BCA protein reagent instructions. The BCA working solution was mixed with the standard protein solution and incubated at 37&#xb0;C for 30 minutes. The microplate reader detects the absorbance at 562nm wavelength. The protein concentration of the samples was calculated by plotting a standard curve.</p>
</sec>
<sec id="s2_3_3">
<title>2.3.3 Acetone Precipitation</title>
<p>100 &#x3bc;g of supernatant protein solution was taken from 10 samples and diluted to 1 mg/ml with RIPA lysis buffer. 4-6 volumes of acetone were added to the EP tube. The EP tubes were shaken at -20&#xb0;C for 30 minutes and then centrifuged at 10,000g at 4&#xb0;C. After centrifugation, the supernatant was removed, and 200 &#x3bc;L of acetone was added to the pellet and washed twice.</p>
</sec>
<sec id="s2_3_4">
<title>2.3.4 Trypsinized Protein</title>
<p>200ul of 100mM ABC (ammonium bicarbonate) (Sigma-Aldrich, St. Louis, MO, USA) with 1% SDC (sodium deoxycholate, Sigma-Aldrich, St. Louis, MO, USA) was added to the protein pellet. The protein precipitate was fully dissolved using ice bath sonication. 5mM disulfide bond reducing agent TCEP (tris 2-carboxyethyl phosphine) (Sigma-Aldrich, St. Louis, MO, USA) was added to each solubilized sample. 10 mmol of indoleacetic acid (Sigma-Aldrich, St. Louis, MO, USA) was added to the EP tube. 2ug trypsin solution (protein:trypsin=50:1) was added to the EP tube containing each sample. The solution in the EP tube was mixed and incubated at 37&#xb0;C for 8 hours.</p>
</sec>
<sec id="s2_3_5">
<title>2.3.5 Extract Polypeptide Liquid</title>
<p>2% TFA (Trifluoroacetic Acid, HPLC) (Sigma-Aldrich, St. Louis, MO, USA) was added to the mixed samples to precipitate SDC in the samples. After high-speed centrifugation, the supernatant was placed in a new EP tube, and TFA was added again to precipitate the peptides. After repeating the same operation 2 times, the supernatants extracted from the 3 operations were mixed. The mixed supernatant was centrifuged again at high speed for 20 minutes. The supernatant after centrifugation was the sample polypeptide.</p>
</sec>
<sec id="s2_3_6">
<title>2.3.6 Desalting of Peptides</title>
<p>0.1% FA (formic acid) (LC-MS, Sigma-Aldrich, St.Louis, MO, USA), 2% ACN (Acetonitrile) (LC-MS, JT Baker, PA, USA), and H<sub>2</sub>O were prepared as buffers A, while buffer B contains only the first two components. The C18 (3M) (Sigma-Aldrich, St. Louis, MO, USA) analytical column was rinsed with buffer A/B, respectively. The steps were repeated once. The eluate was collected after low-speed centrifugation. The eluate was lyophilized under vacuum. Buffer A was added to the lyophilized eluate to reconstitute the peptide to 1 ug/ul for LC-MS/MS detection.</p>
</sec>
<sec id="s2_3_7">
<title>2.3.7 Liquid Chromatography-Tandem Mass Spectrometry Detection (LC-MS/MS)</title>
<p>A 2 &#x3bc;g peptide sample was taken from each component for separation by an ultra-high performance liquid chromatography system EASY-nLC1200 (Thermo Fisher Scientific, USA). Detection was performed using an online mass spectrometer Q-Exactive (Thermo Fisher Scientific, USA). Three technical replicates were performed for each protein sample.</p>
</sec>
<sec id="s2_3_8">
<title>2.3.8 MaxQuant Analysis and LFQ Quantification</title>
<p>MaxQuant (Version 1.5.6.0) was used to analyze raw LC-MS/MS detection data to obtain peptide sequence information. The sequence information was entered into the UniProt protein database (uniport human 20181016 iso-ZL) for forward and reverse sequence searches and protein identification. The quantitation type was set to label-free quantification (LFQ) with inter-run detection.</p>
</sec>
</sec>
<sec id="s2_4">
<title>2.4 Clinical Data Analysis</title>
<p>LASSO regression was used to analyze the training set data to obtain non-zero coefficient parameters. These parameters were included in logistic regression analysis, and then parameters with P&lt;0.05 were selected to construct nomograms. C-index, calibration curve, ROC curve, and DCA curve were used to evaluate the nomogram. The same parameters were chosen to construct the nomogram from the validation set data. The C-index, calibration curve, ROC curve and DCA curve were also used to evaluate the validation set nomogram.</p>
</sec>
<sec id="s2_5">
<title>2.5 Immune Cells Score</title>
<p>We calculated 22 immune cells scores for each sample based on the R language &#x201c;CIBERSORT&#x201d; package.</p>
</sec>
<sec id="s2_6">
<title>2.6 Bioinformatics Analysis</title>
<sec id="s2_6_1">
<title>2.6.1 Calculate DEPs</title>
<p>We log2-transformed raw protein expression data and calculated DEPs using the &#x201c;limma&#x201d; package. Proteins with |Log Fold change (FC) |&gt;2 and P.Value &lt;0.05 were identified as DEPs.</p>
</sec>
<sec id="s2_6_2">
<title>2.6.2 GO Enrichment Analysis</title>
<p>The &#x201c;enrichGO&#x201d; package was run in the R language for functional enrichment analysis, including molecular function (MF), biological process (BP) and cellular component (CC) analysis. We also use the R language to run the &#x201c;enrichKEGG&#x201d; package for KEGG analysis. The 5 most protein counts enrichment analysis results were selected for plotting.</p>
</sec>
<sec id="s2_6_3">
<title>2.6.3 PPI Network Construction</title>
<p>PPI Network analysis was performed using the online protein database(<uri xlink:href="https://string-db.org/">https://string-db.org/</uri>). All DEPs were included in the calculation. The online database sets composite score &gt;0.4. The exported results were imported into Cytoscape software for further analysis.</p>
</sec>
<sec id="s2_6_4">
<title>2.6.4 Key Proteins</title>
<p>We identified key proteins with reference to previous research methods (<xref ref-type="bibr" rid="B13">13</xref>). Cytoscape software was used to calculate the top 30 hub proteins by Degree, Closeness, and MCC methods from PPI networks, respectively. Key proteins were screened from the co-intersection of hub proteins and the proteins of the Coronavirus disease-COVID-19 pathway.</p>
</sec>
</sec>
<sec id="s2_7">
<title>2.7 Statistical Analysis</title>
<p>This paper used R software (version 4.1) for statistical analysis. Cytoscape software (version 3.9) was used to calculate hub proteins. Measurement data were expressed as mean &#xb1; SD. P &lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="s3">
<title>3 Results</title>
<sec id="s3_1">
<title>3.1 Lymphocytes as Predictors of STB</title>
<sec id="s3_1_1">
<title>3.1.1 Patient Characteristics</title>
<p>A total of 1000 patients&#x2019; clinical data were collected in this paper, including 600 cases for constructing the training set and 400 cases for external validation. The clinical characteristics of the STB group and the non-TB spinal group were shown in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Clinical characteristics of patients in the spinal tuberculosis and the non-spinal tuberculosis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Characteristics</th>
<th valign="top" align="center">Non-tuberculosis spinal disease (N = 504)</th>
<th valign="top" align="center">Spinal tuberculosis (N = 496)</th>
<th valign="top" align="center">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="4" align="left">Gender</td>
</tr>
<tr>
<td valign="top" align="left">female</td>
<td valign="top" align="center">73 (14 %)</td>
<td valign="top" align="center">199 (40 %)</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">male</td>
<td valign="top" align="center">431 (86 %)</td>
<td valign="top" align="center">297 (60 %)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Age</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">35.0 &#xb1; 10.5</td>
<td valign="top" align="center">50.2 &#xb1; 17.5</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">BMI</td>
</tr>
<tr>
<td valign="top" align="left">&lt;18.5</td>
<td valign="top" align="center">29 (6 %)</td>
<td valign="top" align="center">130 (26 %)</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">18.5~23.9</td>
<td valign="top" align="center">379 (75 %)</td>
<td valign="top" align="center">317 (64 %)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">&gt;23.9</td>
<td valign="top" align="center">96 (19 %)</td>
<td valign="top" align="center">49 (10 %)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" colspan="4" align="left">ESR</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">30.1 &#xb1; 22.0</td>
<td valign="top" align="center">41.7 &#xb1; 30.6</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">CRP</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">29.4 &#xb1; 38.2</td>
<td valign="top" align="center">30.1 &#xb1; 39.5</td>
<td valign="top" align="center">0.766</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">White blood cells</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">8.25 &#xb1; 2.09</td>
<td valign="top" align="center">7.31 &#xb1; 2.82</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Hemoglobin</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">132 &#xb1; 18.0</td>
<td valign="top" align="center">120 &#xb1; 17.5</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Platelets</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">317 &#xb1; 98.1</td>
<td valign="top" align="center">305 &#xb1; 103</td>
<td valign="top" align="center">0.043</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Percentage of neutrophils</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">0.627 &#xb1; 0.0986</td>
<td valign="top" align="center">0.632 &#xb1; 0.122</td>
<td valign="top" align="center">0.466</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Neutrophils</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">5.26 &#xb1; 1.87</td>
<td valign="top" align="center">4.76 &#xb1; 2.54</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Percentage of lymphocytes</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">0.268 &#xb1; 0.0902</td>
<td valign="top" align="center">0.235 &#xb1; 0.105</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Lymphocytes</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">2.13 &#xb1; 0.740</td>
<td valign="top" align="center">1.61 &#xb1; 0.827</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Monocytes</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">0.636 &#xb1; 0.238</td>
<td valign="top" align="center">0.651 &#xb1; 0.280</td>
<td valign="top" align="center">0.374</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">Percentage of monocytes</td>
</tr>
<tr>
<td valign="top" align="left">Mean &#xb1; SD</td>
<td valign="top" align="center">0.0782 &#xb1; 0.0250</td>
<td valign="top" align="center">0.0974 &#xb1; 0.0600</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_1_2">
<title>3.1.2 Building a Nomogram Predictive Model</title>
<p>All parameters were included in LASSO regression analysis. The binomial deviation was plotted through the optimal log (Lambda) value (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). Coefficient plots for LASSO regression were also plotted by log (Lambda) values. 12 non-zero coefficient parameters are screened by the optimal log (Lambda) value (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>). These parameters with non-zero coefficients were included in logistic regression analysis. The results showed statistical differences in 4 parameters, including gender, age, BMI, and lymphocytes (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). These four parameters were then chosen to construct the nomogram. The nomogram of the training set predicted the risk of STB ranging from 0.1 to 0.994 (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>). The nomogram of the external validation set also predicted risk in the same range from 0.1 to 0.994 (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Parameters were selected to build LASSO regression and nomogram models. <bold>(A)</bold> The binomial deviation was plotted through the optimal log (Lambda) value. <bold>(B)</bold> 12 non-zero coefficient parameters are screened by the optimal log (Lambda) value. <bold>(C)</bold> The nomogram predicting the risk of spinal tuberculosis was plotted in the training set. <bold>(D)</bold> The nomogram predicting the risk of spinal tuberculosis was plotted in the external validation set.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g003.tif"/>
</fig>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Multivariate logistic regression analysis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Characteristics</th>
<th valign="top" align="center">OR</th>
<th valign="top" align="center">95%CI</th>
<th valign="top" align="center">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Gender(male)</td>
<td valign="top" align="center">0.260</td>
<td valign="top" align="center">0.147-0.451</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Age</td>
<td valign="top" align="center">1.076</td>
<td valign="top" align="center">1.058-1.096</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" colspan="4" align="left">BMI</td>
</tr>
<tr>
<td valign="top" align="left">18.5~23.9</td>
<td valign="top" align="center">0.081</td>
<td valign="top" align="center">0.038-0.163</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">&gt;23.9</td>
<td valign="top" align="center">0.049</td>
<td valign="top" align="center">0.019-0.117</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Lymphocytes</td>
<td valign="top" align="center">0.332</td>
<td valign="top" align="center">0.179-0.599</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Female in gender and BMI &lt;18.5 were used as reference values for analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_1_3">
<title>3.1.3 Evaluating the Nomogram Prediction Model</title>
<p>The C-index of the nomogram constructed from the training set was 0.872 (95% CI: 0.845-0.899). The C-index of the training set calculated by the internal validation method was 0.866. The nomogram C-index of the external validation set was also as high as 0.848 (95%CI: 0.811-0.885). The calibration curve for the training set showed that the nomogram predicted risk of STB was highly consistent with the actual diagnosis of STB (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). Interestingly, the calibration curve for the external validation set showed that the predicted and actual values were also highly consistent (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). The ROC curve of the training set showed that the AUC of the nomogram model for predicting STB was 0.862 (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>). Similarly, the ROC curve of the external validation set calculated the AUC to be 0.834 (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4D</bold>
</xref>). The DCA curve of the training set showed that the net benefit of the predictive model ranged from 0.01 to 0.99(<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4E</bold>
</xref>), which was consistent with that of the external validation set (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4F</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>The predictive ability and accuracy of the nomogram model was evaluated. <bold>(A)</bold> The calibration curve for the training set showed that the nomogram predicted risk of spinal tuberculosis was highly consistent with the actual diagnosis of spinal tuberculosis. <bold>(B)</bold> The calibration curve for the external validation set showed that the predicted and actual values were also highly consistent. <bold>(C)</bold> The ROC curve of the training set showed that the AUC of the nomogram model for predicting spinal tuberculosis was 0.862. <bold>(D)</bold> The ROC curve of the external validation set calculated the AUC to be 0.834. <bold>(E)</bold> The DCA curve of the training set showed that the net benefit of the predictive model ranged from 0.01 to 0.99. <bold>(F)</bold>, The DCA curve of the external validation set showed that the net benefit of the predictive model also ranged from 0.01 to 0.99.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g004.tif"/>
</fig>
</sec>
<sec id="s3_1_4">
<title>3.1.4 Lymphocytes Expression</title>
<p>We found that the lymphocytes were 1.61 &#xb1; 0.83 X10<sup>9</sup>/L in STB and 2.13 &#xb1; 0.74 X 10<sup>9</sup>/L in non-TB spinal disease(<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>). There was a statistically significant difference between the two groups(P&lt;0.001).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Immune cells analysis. <bold>(A)</bold> Comparison of lymphocytes in spinal tuberculosis and nontuberculous spinal disease. <bold>(B)</bold> The estimated distribution of 22 immune cells was plotted. <bold>(C)</bold> The expression ratio of 22 immune cells in each sample was plotted. <bold>(D)</bold> Heatmap showed expression of immune cells in spinal tuberculosis and non-spinal tuberculosis tissues and showed that the expression of B cells naive former tissues was lower than that in the latter tissues. ***:P&lt;0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="s3_2">
<title>3.2 Immune Cell Analysis</title>
<p>A total of 1965 proteins were identified in 10 intervertebral disc samples, including 5 STB disc samples and 5 non-TB spinal disc samples. The estimated distribution of 22 immune cells showed that the three cells with the highest distribution in the sample were B cells naive, platelet cells, and NK cells resting (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>). Immune cells for each sample were displayed by histograms and B cells naive had higher expression levels in each sample (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5C</bold>
</xref>). Heatmap of 10 clinical samples showed a clear degree of clustering of B cells naive in spinal tissue and non-TB spinal tissue (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5D</bold>
</xref>).</p>
<p>The comparison of 22 immune cells scores in the STB group and the non-TB spinal group was shown in the violin plot (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>). There were statistical differences among the three types of immune cells, including B cells naive(P=0.016), platelet cells (P=0.008), and NK cells activated (P=0.045).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Violin, volcano, and heatmap were plotted. <bold>(A)</bold> The comparison of 22 immune cell scores in spinal tuberculosis and non-spinal tuberculosis was plotted by the violin plot. There were statistical differences among the three types of immune cells, including B cells naive, platelet cells, and NK cells activated. <bold>(B)</bold> The volcano plot showed that the differential proteins were divided into up-regulated and down-regulated proteins. <bold>(C)</bold> The heatmap clearly showed the clustering of the top 50 proteins in spinal tuberculosis tissues and non-spinal tuberculosis tissues.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g006.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>3.3 Protein Bioinformatics Analysis</title>
<sec id="s3_3_1">
<title>3.3.1 DEPs Analysis</title>
<p>The sample proteins were analyzed by LC-MS/MS, and 1965 quantifiable proteins were identified. The conditions for calculating differential proteins were set as logFoldChange&gt;2 and P.Value&lt;0.05. A total of 350 DEPs were screened, including 86 down-regulated proteins and 264 up-regulated proteins. The volcano plot showed that the DEPs were divided into up-regulated and down-regulated proteins (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>). The&#xa0;heatmap clearly showed the clustering of the top 50 proteins in STB tissue and non-TB spinal tissue (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref>).</p>
</sec>
<sec id="s3_3_2">
<title>3.3.2 GO Functional Enrichment Analysis</title>
<p>All DEPs were selected to GO functional enrichment analysis, and the screening conditions were set as p.value and p.adjust were both less than 0.05. BP functional enrichment had 284 entries. The 5 entries with the most enriched protein counts were plotted, including protein targeting, neutrophil activation, neutrophil degranulation, neutrophil activation involved in immune response, and neutrophil mediated immunity (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7A</bold>
</xref>). The CC functional enrichment had 106 entries. The 5 entries with the most enriched protein counts were plotted, including collagen-containing extracellular matrix, focal adhesion, cell-substrate junction, mitochondrial inner membrane and cytosolic ribosome (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7B</bold>
</xref>). The MF functional enrichment had 55 entries. The 5 entries with the most enriched protein counts were plotted, including structural constituent of ribosome, extracellular matrix structural constituent, actin binding, glycosaminoglycan binding and sulfur compound binding (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7C</bold>
</xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>GO and KEGG pathway enrichment analyses were plotted. <bold>(A)</bold> BP functional enrichment had 284 entries. The 5 entries with the most enriched protein counts were plotted. <bold>(B)</bold> CC functional enrichment had 284 entries. The 5 entries with the most enriched protein counts were plotted. <bold>(C)</bold> MF functional enrichment had 284 entries. The 5 entries with the most enriched protein counts were plotted. <bold>(D)</bold> KEGG pathway enrichment had 284 entries. The 5 entries with the most enriched protein counts were plotted.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g007.tif"/>
</fig>
</sec>
<sec id="s3_3_3">
<title>3.3.3 KEGG Pathway Enrichment Analysis</title>
<p>All DEPs were selected for KEGG pathway enrichment analysis, and the screening conditions were set as p.value and p.adjust were both less than 0.05. 26 KEGG pathways were enriched. The 5 KEGG pathways with the most protein counts were plotted, including Coronavirus disease - COVID-19, ribosome, diabetic cardiomyopathy, chemical carcinogenesis - reactive oxygen species and prion disease (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7D</bold>
</xref>). Coronavirus disease - COVID-19 was enriched for the most proteins by the KEGG pathway, including 34 proteins that might play important roles in STB.</p>
</sec>
<sec id="s3_3_4">
<title>3.3.4 PPI Network Construction</title>
<p>All DEPs were included in the construction of the PPI network analysis. Furthermore, Cytoscape software was used for drawing and analysis. The differential proteins were divided into up-regulated proteins and down-regulated proteins by constructing a PPI network map. Outer circle proteins indicated up-regulated proteins and inner circle proteins indicated down-regulated proteins (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8</bold>
</xref>).</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>The differential proteins were divided into up-regulated proteins and down-regulated proteins by constructing a PPI network map. Outer circle proteins indicated up-regulated proteins and inner circle proteins indicated down-regulated proteins.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g008.tif"/>
</fig>
</sec>
<sec id="s3_3_5">
<title>3.3.5 Identification of Key Proteins</title>
<p>Cytoscape software calculated the hub 30 key proteins by Closeness, Degree, and MCC methods, respectively. A total of 13 hub proteins were obtained by the intersection of three methods (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9A</bold>
</xref>). These proteins again underwent a secondary Venn diagram intersection with proteins of the KEGG pathway Coronavirus disease - COVID-19. There were 9 key proteins in the intersection of the hub proteins calculated by Cytoscape and the COVID-19-related proteins (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9B</bold>
</xref>). These 9 key proteins were RPS6, RPL23, RPS9, RPL5, RPL13A, RPS3, RPL4, RPL9 and RPL19.</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>
<bold>(A, B)</bold> Venn diagrams were plotted. <bold>(A)</bold> Cytoscape software calculated the hub 30 key proteins by Closeness, Degree, and MCC methods, respectively. A total of 13 hub proteins were obtained by the intersection of three methods. <bold>(B)</bold> There were 9 key proteins in the intersection of the hub proteins calculated by Cytoscape and the proteins of the Coronavirus disease-COVID-19 pathway. <bold>(C, D)</bold> Differential analysis of immune-related genes. <bold>(C)</bold> 30 immune-related genes include 7 down-regulated genes and 23 up-regulated genes. <bold>(D)</bold> The circus heatmap clearly showed the clustering of all the immune-related genes in STB tissue and non-TB spinal tissue.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g009.tif"/>
</fig>
</sec>
</sec>
<sec id="s3_4">
<title>3.4 Immune-Related Genes</title>
<p>Among all DEPs, we found 30 immune-related genes, including 7 down-regulated genes and 23 up-regulated genes (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9C</bold>
</xref>). The circus heatmap clearly showed the clustering of all the immune-related genes in STB tissue and non-TB spinal tissue (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9D</bold>
</xref>).</p>
</sec>
<sec id="s3_5">
<title>3.5 Correlation Between COVID-19-Related Proteins and Immune Regulation</title>
<p>In STB tissue, we found that the immune gene CD14 was positively correlated with B cells naive (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10A</bold>
</xref>). However, the COVID-19-related protein RPL19 was negatively correlated with CD14 (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10B</bold>
</xref>) and B cells naive (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10C</bold>
</xref>). RPL19 may inhibit the expression of immune B cells naive in STB by regulating the expression of CD14. The immune gene LYN was negatively correlated with ODI (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10D</bold>
</xref>). There was a positive correlation between COVID-19-related protein RPL23 and LYN (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10E</bold>
</xref>). However, RPL23 was negatively correlated with ODI (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10F</bold>
</xref>). There was a positive correlation between the immune gene RAF1 and ODI (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10G</bold>
</xref>). However, RPL23 was negatively correlated with RAF1(<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10H</bold>
</xref>).RPL23 may reduce ODI score in STB by regulating the expression of LYN and RAF1. There was a positive correlation between COVID-19-related protein RPS6 and TAP2(<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10I</bold>
</xref>). The immune gene TAP2 was negatively correlated with VAS (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10J</bold>
</xref>). Similarly, RPS6 was negatively correlated with VAS (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10K</bold>
</xref>). There was a positive correlation between RPS6 and the immune gene STAT1 (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10L</bold>
</xref>). However, STAT1 was negatively correlated with VAS (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10M</bold>
</xref>). The immune gene IGF2R was negatively correlated with VAS (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10N</bold>
</xref>). However, there was a positive correlation between RPS6 and IGF2R (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10O</bold>
</xref>). RPS6 may reduce the VAS score of STB patients by regulating the expression of TAP2, STAT1 and IGF2R.</p>
<fig id="f10" position="float">
<label>Figure&#xa0;10</label>
<caption>
<p>Correlation analysis was plotted. <bold>(A)</bold> Correlation analysis of B cells naive and CD14. <bold>(B)</bold> Correlation analysis of RPL19 and CD14. <bold>(C)</bold> Correlation analysis of B cells naive and RPL19. <bold>(D)</bold> Correlation analysis of LYN and ODI. <bold>(E)</bold> Correlation analysis of RPL23 and LYN. <bold>(F)</bold> Correlation analysis of RPL23 and ODI. <bold>(G)</bold> Correlation analysis of RAF1 and ODI. <bold>(H)</bold> Correlation analysis of RPL23 and RAF1. <bold>(I)</bold> Correlation analysis of TAP2 and RPS6. <bold>(J)</bold> Correlation analysis of TAP2 and VAS. <bold>(K)</bold> Correlation analysis of RPS6 and VAS. <bold>(L)</bold> Correlation analysis of RPS6 and STAT1. <bold>(M)</bold> Correlation analysis of STAT1and VAS. <bold>(N)</bold> Correlation analysis of IGF2R and VAS. <bold>(O)</bold> Correlation analysis of RPS6 and IGF2R.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g010.tif"/>
</fig>
<p>There was a positive correlation between the COVID-19-related protein RPS9 and STAT1 (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11A</bold>
</xref>). There was a negative correlation between VAS and RPS9 (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11B</bold>
</xref>). Similarly, VAS was negatively correlated with STAT1 (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11C</bold>
</xref>). In addition, there was a positive correlation between RPS9 and IGF2R (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11D</bold>
</xref>). RPS9 may reduce the VAS score of STB patients by regulating the expression of STAT1 and IGF2R. There was a positive correlation between the COVID-19-related protein RPL9 and IGF2R (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11E</bold>
</xref>). However, RPL9 was negatively correlated with VAS (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11F</bold>
</xref>).RPL9 may reduce the VAS score of STB patients by regulating the expression of IGF2R. The COVID-19-related protein RPL13A was negatively correlated with VAS (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11G</bold>
</xref>). However, RPL13A positively correlated with both TAP2 (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11H</bold>
</xref>) and IGF2R (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11I</bold>
</xref>). RPL13A may reduce the VAS score of STB patients by regulating the expression of TAP2 and IGF2R. There was a positive correlation between the COVID-19-related protein RPS3 and IGF2R (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11J</bold>
</xref>). However, there was a positive correlation between RPS3 and VAS (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11K</bold>
</xref>). RPS3 was positively correlated with both TAP2 (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11L</bold>
</xref>) and STAT1 (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11M</bold>
</xref>). RPS3 may reduce the VAS score of STB patients by regulating the expression of IGF2R, TAP2 and STAT1. In addition, we found a positive correlation between the COVID-19-related protein RPL4 and JOA (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11N</bold>
</xref>). However, RPL4 was negatively correlated with ODI (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11O</bold>
</xref>). Immune genes were not involved in RPL4 regulation of JOA and ODI scores of STB patients.</p>
<fig id="f11" position="float">
<label>Figure&#xa0;11</label>
<caption>
<p>Correlation analysis was plotted. <bold>(A)</bold> Correlation analysis of STAT1 and RPS9. <bold>(B)</bold> Correlation analysis of RPS9 and VAS. <bold>(C)</bold> Correlation analysis of STAT1 and VAS. <bold>(D)</bold> Correlation analysis of IGF2R and RPS9. <bold>(E)</bold> Correlation analysis of RPL9 and IGF2R. <bold>(F)</bold> Correlation analysis of RPL9 and VAS. <bold>(G)</bold> Correlation analysis of RPL13A and VAS. <bold>(H)</bold> Correlation analysis of RPL13A and TAP2. <bold>(I)</bold> Correlation analysis of IGF2R and RPL13A. <bold>(J)</bold> Correlation analysis of IGF2R and RPS3. <bold>(K)</bold> Correlation analysis of RPS3 and VAS. <bold>(L)</bold> Correlation analysis of RPS3 and TAP2. <bold>(M)</bold> Correlation analysis of STAT1and RPS3. <bold>(N)</bold> Correlation analysis of RPL4 and JOA. <bold>(O)</bold> Correlation analysis of RPL4 and ODI.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g011.tif"/>
</fig>
<p>A Sankey diagram was plotted showing the relationship between COVID-19-related proteins regulating immune genes and clinical scores (<xref ref-type="fig" rid="f12">
<bold>Figure&#xa0;12</bold>
</xref>).</p>
<fig id="f12" position="float">
<label>Figure&#xa0;12</label>
<caption>
<p>A Sankey diagram was plotted showing the relationship between COVID-19-related proteins regulating immune genes and clinical scores.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-882651-g012.tif"/>
</fig>
</sec>
</sec>
<sec id="s4">
<title>4 Discussion</title>
<p>STB was an infectious disease caused by M. TB invading the intervertebral discs and vertebral bodies. There were many methods for the diagnosis of STB, the most authoritative of which was a pathological examination. However, early STB had limitations in diagnosing without pathological examination. We collected 1000 cases of clinical data. Lymphocytes were screened by LASSO regression and Logistic regression methods. Lymphocytes were used to construct nomograms and played an important role in predicting the risk of STB. To further verify the role of immune cells in STB, we collected 10 intervertebral disc samples. A total of 1965 quantifiable proteins were identified. The results of immune cells scoring indicated that B cells naive were differentially expressed in STB. Both the B cells naive of the intervertebral disc tissue and the lymphocytes of the blood were lowly expressed in STB. DEPs were enriched to a Coronavirus disease-COVID-19 pathway by KEGG enrichment analysis. In addition, we referred to previous research strategies, which identified common key genes through enrichment analysis and modules (<xref ref-type="bibr" rid="B13">13</xref>). We also used the COVID-19 KEGG enrichment pathway and the three modules of MCC, Closeness, and Degree to identify key proteins.</p>
<p>M. TB was mainly phagocytosed by macrophages. The source of macrophages evolved from monocytes. Therefore, the expression of monocytes in the blood was usually increased in STB. However, lymphocytes act as immune cells, and M. TB suppresses the immune function of the body to avoid being killed, which might lead to suppressed immune cells expression. The study by Lv et&#xa0;al. found that the lymphocytes of non-TB were 1.48&#x2009;&#xb1;&#x2009;0.05, that of pulmonary TB was 1.31&#x2009;&#xb1;&#x2009;0.08, and that of extrapulmonary TB was 1.23&#x2009;&#xb1;&#x2009;0.06 (<xref ref-type="bibr" rid="B18">18</xref>). The number of lymphocytes in non-TB was significantly decreased, and the comparison was statistically significant(P=0.004). M. TB was effectively controlled after CD8+ T lymphocytes were inhibited (<xref ref-type="bibr" rid="B19">19</xref>). As a member of the NLR family, NLRC3 effectively inhibited the expression of CD4+ T cells and promoted M. TB infection (<xref ref-type="bibr" rid="B20">20</xref>). Similarly, our study found that lymphocytes in STB were significantly lower than those in the non-TB spinal group. Lymphocytes played an important role in the model predicting the risk of STB.</p>
<p>B lymphocytes might play a role in the immune escape of M. TB. A study by Corominas et&#xa0;al. showed that 35 TB patients had significantly lower B lymphocytes than 20 healthy patients (<xref ref-type="bibr" rid="B21">21</xref>). In M. TB -infected mice with knockout B cells, bacterial load was significantly increased compared to wild-type mice (<xref ref-type="bibr" rid="B22">22</xref>). However, TB granulomas developed in mice with reconstituted naive B cells, a widespread form consistent with wild-type mice (<xref ref-type="bibr" rid="B23">23</xref>). After M. TB activation, naive B cells secrete M. TB -specific antibodies and release cytokines, and naive B cells further develop into activated plasma cells (<xref ref-type="bibr" rid="B24">24</xref>). In this paper, the B cells naive of TB tissue was significantly lower than that of non-TB tissue in the immune cells score. This might be that M. TB infection suppressed the immune response of B lymphocytes, or that M. TB was activated in macrophages and stimulated the development of B cells into activated plasma cells.</p>
<p>In this study, the DEPs were included in the KEGG enrichment analysis, and a Coronavirus disease-COVID-19 KEGG pathway was enriched. Although there was no evidence that COVID-19 induced TB or that TB induced COVID-19, there had been reports in the literature of COVID-19 complicated with TB (<xref ref-type="bibr" rid="B25">25</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>). The predisposing factors of COVID 19 were similar to those of TB, such as HIV, COPD, diabetes, alcohol abuse, and smoking (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). In patients with COVID 19, isolated TB foci had been reported in bone, spinal in location, and other sites (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). The relationship between TB and COVID 19 might be linked to BCG injection. For every 10% increase in BCG administration, there was a 10.4% reduction in COVID 19 mortality (<xref ref-type="bibr" rid="B28">28</xref>&#x2013;<xref ref-type="bibr" rid="B30">30</xref>). Mortality rates from COVID 19 were lower in seven countries where BCG was mandatory, compared to countries that stopped BCG for 20 years (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). However, there was no literature on how co-infection between COVID-19 and TB occurred. Whether patients with STB who carry COVID-19-related proteins are more prone to TB combined with COVID-19 under exposure to COVID-19 virus, which needs further study.</p>
<p>Although the TB patient data we collected did not have a confirmed diagnosis of COVID-19, a Coronavirus disease-COVID-19 pathway was identified by KEGG enrichment analysis. There was a total of 34 proteins in this pathway, including CYBB, STAT1, OAS3, C5AR1, CXCL10, and ribosomal proteins. It might be that the DEPs expressed in TB were also differentially expressed in COVID-19. The spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) inhibited STAT1 activation, blocked its association with the JAK1 pathway, and then inhibited the host type I interferon response (<xref ref-type="bibr" rid="B31">31</xref>). In addition, SARS-CoV-2 spike protein interacted with dendritic cells to activate inflammatory pathways including MAPK, AKT, STAT1, and NF-&#x3ba;B and promoted the release of inflammatory cytokines (<xref ref-type="bibr" rid="B32">32</xref>). OAS3 was identified as one of the highly conserved genes in type I interferon response, regulating IFN-I signaling, and contributing to the diagnosis of COVID-19 (<xref ref-type="bibr" rid="B33">33</xref>). OAS3 was also identified as predicting the severity of COVID-19 (<xref ref-type="bibr" rid="B34">34</xref>). CXCL10 was released along with pro-inflammatory mechanisms that promoted pulmonary fibrosis in COVID-19 patients through the CXCL10-CXCR3 signaling system and CXCL10 was identified with a poor prognosis in COVID-19 patients (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). The ribosomal protein family was widely expressed in the Coronavirus disease-COVID-19 pathway. Our differential protein bioinformatics analysis identified 29 ribosomal proteins. Both mitochondrial and cytoplasmic ribosomal proteins were closely associated with SARS-CoV-2 longest non-structural protein 3 (NSP3), which played a role in RNA metabolism and immune responses (<xref ref-type="bibr" rid="B37">37</xref>). A large number of ribosomal proteins and viral mRNAs were involved in viral protein biosynthesis, and these proteins were important for viral replication and infection of host cells. RPL 9 and RPL 10 could be used to assess the activity of Covid-19 and even became targets for the development of Covid-19 vaccines and treatments (<xref ref-type="bibr" rid="B38">38</xref>).</p>
<p>In this paper, we found that nine key proteins related to COVID-19 were involved in the regulation of STB through immune genes. RPL19 might suppress STB immune B cells naive by regulating the immune gene CD14. The study by Wang et&#xa0;al. showed that RPL19 and CD14 were involved in the immune response intracellularly (<xref ref-type="bibr" rid="B39">39</xref>). In addition, the gene polymorphism of CD14 was a high-risk factor for STB (<xref ref-type="bibr" rid="B40">40</xref>). We found that RPS3 was negatively associated patient&#x2019;s VAS. RPS3 synergistically enhanced DNA binding with P65 and P65-P50. Once RPS3 was knocked out, the transcriptional function of NF-&#x3ba;B subunit P65 was affected (<xref ref-type="bibr" rid="B41">41</xref>). BfrB impeded NF-&#x3ba;B function by inhibiting the nuclear abundance of RPS3, resulting in reduced host innate immunity against M. TB infection (<xref ref-type="bibr" rid="B42">42</xref>). RPS6 had involved in the transformation of M. TB S18 ribosomal proteins along with Zinc (<xref ref-type="bibr" rid="B43">43</xref>). In this paper, RPS6 could also regulate the expression of immune genes TAP2, STAT1 and IGF2R to suppress VAS in patients.</p>
<p>In addition, the systemic endocrine system may also be involved in the immune dysregulation of COVID-19 (<xref ref-type="bibr" rid="B44">44</xref>). Spinal tuberculosis usually suffered from vertebral body destruction with coexisting osteogenic and osteoclastic processes (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). The RANK-RANKL pathway not only played an important role in regulating the mechanism of osteoclasts (<xref ref-type="bibr" rid="B47">47</xref>). In addition, RANK-RANKL was also involved in immune regulation to modulate lymph node maturation, immunosuppression and presenting cell activity, and further participated in lymphocyte self-tolerance (<xref ref-type="bibr" rid="B48">48</xref>).</p>
<p>However, this study still had some limitations. (1) The clinical data was a single-center study, and a multi-center study was required to validate the nomogram model. (2) Tissue samples for COVID-19 with STB could not be collected for experimental verification.</p>
</sec>
<sec id="s5">
<title>5 Conclusion</title>
<p>Lymphocytes were predictive factors for the diagnosis of STB. Immune cells showed low expression in STB. Nine COVID-19-related proteins were involved in STB mechanisms, including RPS6, RPL23, RPS9, RPL5, RPL13A, RPS3, RPL4, RPL9, and RPL19. These nine key proteins may suppress the immune mechanism of STB by regulating the expression of immune genes.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The data presented in the study are deposited in the NCBI repository, accession number PRJNA841580.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by the ethics committee of The First Affiliated Hospital of Guangxi Medical University. The patients/participants provided their written informed consent to participate in the study.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author Contributions</title>
<p>LC wrote the article and prepared figures and tables. CL, this author contributed&#x2002;equally&#x2002;to&#x2002;this&#x2002;work&#x2002;and&#x2002;should&#x2002;be considered&#x2002;co-first&#x2002;authors. ZG and XZ have shared contributions and should be considered co-corresponding authors. All authors reviewed the article. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>This work was sponsored by the National Natural Science Foundation of China (81560359); National Natural Science Foundation of China (81860393). Funding bodies had no role in the study design, collection, analysis, and interpretation of the data or in writing the manuscript.</p>
</sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakaya</surname> <given-names>J</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ntoumi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Aklillu</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fatima</surname> <given-names>R</given-names>
</name>
<name>
<surname>Mwaba</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Global Tuberculosis Report 2020 - Reflections on the Global TB Burden, Treatment and Prevention Efforts</article-title>. <source>Int J Infect Dis</source> (<year>2021</year>) <volume>113 Suppl 1</volume>(<supplement>Suppl 1</supplement>):<fpage>S7</fpage>&#x2013;<lpage>s12</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2021.02.107</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Nijs</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Spinal Tuberculosis</article-title>. <source>Lancet (London England)</source> (<year>9807</year>) <volume>2011</volume>:<fpage>378</fpage>:<elocation-id>e18</elocation-id>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61482-7</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname> <given-names>RK</given-names>
</name>
<name>
<surname>Somvanshi</surname> <given-names>DS</given-names>
</name>
</person-group>. <article-title>Spinal Tuberculosis: A Review</article-title>. <source>J Spinal Cord Med</source> (<year>2011</year>) <volume>34</volume>(<issue>5</issue>):<page-range>440&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.1179/2045772311Y.0000000023</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batirel</surname> <given-names>A</given-names>
</name>
<name>
<surname>Erdem</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sengoz</surname> <given-names>G</given-names>
</name>
<name>
<surname>Pehlivanoglu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ramosaco</surname> <given-names>E</given-names>
</name>
<name>
<surname>G&#xfc;ls&#xfc;n</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The Course of Spinal Tuberculosis (Pott Disease): Results of the Multinational, Multicentre Backbone-2 Study</article-title>. <source>Clin Microbiol infection</source> (<year>2015</year>) <volume>21</volume>(<issue>11</issue>):<fpage>e9</fpage>&#x2013;<lpage>1008.e18</lpage>:<fpage>1008</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2015.07.013</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussell</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bell</surname> <given-names>TJ</given-names>
</name>
</person-group>. <article-title>Alveolar Macrophages: Plasticity in a Tissue-Specific Context</article-title>. <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>(<issue>2</issue>):<fpage>81</fpage>&#x2013;<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri3600</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrelles</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Schlesinger</surname> <given-names>LS</given-names>
</name>
</person-group>. <article-title>Integrating Lung Physiology, Immunology, and Tuberculosis</article-title>. <source>Trends Microbiol</source> (<year>2017</year>) <volume>25</volume>(<issue>8</issue>):<page-range>688&#x2013;97</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2017.03.007</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roca</surname> <given-names>F</given-names>
</name>
<name>
<surname>Whitworth</surname> <given-names>L</given-names>
</name>
<name>
<surname>Redmond</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ramakrishnan</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>TNF Induces Pathogenic Programmed Macrophage Necrosis in Tuberculosis Through a Mitochondrial-Lysosomal-Endoplasmic Reticulum Circuit</article-title>. <source>Cell</source> (<year>2019</year>) <volume>178</volume>(<issue>6</issue>):<fpage>1344</fpage>&#x2013;<lpage>1361.e11</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2019.08.004</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joosten</surname> <given-names>SA</given-names>
</name>
<name>
<surname>van Meijgaarden</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Del Nonno</surname> <given-names>F</given-names>
</name>
<name>
<surname>Baiocchini</surname> <given-names>A</given-names>
</name>
<name>
<surname>Petrone</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vanini</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Patients With Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes Following Successful Treatment</article-title>. <source>PloS Pathog</source> (<year>2016</year>) <volume>12</volume>(<issue>6</issue>):<elocation-id>e1005687</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1005687</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abreu</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Carvalheiro</surname> <given-names>H</given-names>
</name>
<name>
<surname>Rodrigues-Sousa</surname> <given-names>T</given-names>
</name>
<name>
<surname>Domingos</surname> <given-names>A</given-names>
</name>
<name>
<surname>Segorbe-Luis</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rodrigues-Santos</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Alterations in the Peripheral Blood B Cell Subpopulations of Multidrug-Resistant Tuberculosis Patients</article-title>. <source>Clin Exp Med</source> (<year>2014</year>) <volume>14</volume>(<issue>4</issue>):<page-range>423&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s10238-013-0258-1</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ardain</surname> <given-names>A</given-names>
</name>
<name>
<surname>Domingo-Gonzalez</surname> <given-names>R</given-names>
</name>
<name>
<surname>Das</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kazer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Howard</surname> <given-names>N</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Group 3 Innate Lymphoid Cells Mediate Early Protective Immunity Against Tuberculosis</article-title>. <source>Nature</source> (<year>2019</year>) <volume>570</volume>(<issue>7762</issue>):<page-range>528&#x2013;32</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41586-019-1276-2</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisht</surname> <given-names>R</given-names>
</name>
<name>
<surname>Saharia</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sarma</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>COVID-19 and the Burden of Ill-Health: A Double Crisis of Disruptions and Inequalities</article-title>. <source>J Soc economic Dev</source> (<year>2020</year>) <volume>p</volume>:<fpage>1</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40847-020-00117-x</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nalbandian</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sehgal</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Madhavan</surname> <given-names>M</given-names>
</name>
<name>
<surname>McGroder</surname> <given-names>C</given-names>
</name>
<name>
<surname>Stevens</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Post-Acute COVID-19 Syndrome</article-title>. <source>Nat Med</source> (<year>2021</year>) <volume>27</volume>(<issue>4</issue>):<page-range>601&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41591-021-01283-z</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karami</surname> <given-names>H</given-names>
</name>
<name>
<surname>Derakhshani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ghasemigol</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fereidouni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Miri-Moghaddam</surname> <given-names>E</given-names>
</name>
<name>
<surname>Baradaran</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Weighted Gene Co-Expression Network Analysis Combined With Machine Learning Validation to Identify Key Modules and Hub Genes Associated With SARS-CoV-2 Infection</article-title>. <source>J Clin Med</source> (<year>2021</year>) <volume>10</volume>(<issue>16</issue>):<fpage>3567</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm10163567</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mishra</surname> <given-names>A</given-names>
</name>
<name>
<surname>George</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sahu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Lal</surname> <given-names>A</given-names>
</name>
<name>
<surname>and Abraham</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Tuberculosis and COVID-19 Co-Infection: An Updated Review</article-title>. <source>Acta BioMed</source> (<year>2020</year>) <volume>92</volume>(<issue>1</issue>):<elocation-id>e2021025</elocation-id>. doi: <pub-id pub-id-type="doi">10.23750/abm.v92i1.10738</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tadolini</surname> <given-names>M</given-names>
</name>
<name>
<surname>Codecasa</surname> <given-names>LR</given-names>
</name>
<name>
<surname>Garc&#xed;a-Garc&#xed;a</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Blanc</surname> <given-names>FX</given-names>
</name>
<name>
<surname>Borisov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Alffenaar</surname> <given-names>JW</given-names>
</name>
<etal/>
</person-group>. <article-title>Active Tuberculosis, Sequelae and COVID-19 Co-Infection: First Cohort of 49 Cases</article-title>. <source>Eur Respir J</source> (<year>2020</year>) <volume>56</volume>(<issue>1</issue>):<fpage>2001398</fpage>. doi: <pub-id pub-id-type="doi">10.1183/13993003.02328-2020</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadanshiv</surname> <given-names>M</given-names>
</name>
<name>
<surname>George</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Kuriakose</surname> <given-names>CK</given-names>
</name>
</person-group>. <article-title>Rifampicin-Induced Immune Allergic Reaction</article-title>. <source>Trop Doct</source> (<year>2018</year>) <volume>48</volume>(<issue>2</issue>):<page-range>156&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1177/0049475517724689</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soko</surname> <given-names>R</given-names>
</name>
<name>
<surname>Burke</surname> <given-names>R</given-names>
</name>
<name>
<surname>Feasey</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sibande</surname> <given-names>W</given-names>
</name>
<name>
<surname>Nliwasa</surname> <given-names>M</given-names>
</name>
<name>
<surname>Henrion</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of Coronavirus Disease Pandemic on Tuberculosis Notifications, Malawi</article-title>. <source>Emerging Infect Dis</source> (<year>2021</year>) <volume>27</volume>(<issue>7</issue>):<page-range>1831&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.3201/eid2707.210557</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Combining Interferon-&#x3b3; Release Assays With Lymphocyte Enumeration for Diagnosis of Mycobacterium Tuberculosis Infection</article-title>. <source>J Int Med Res</source> (<year>2020</year>) <volume>48</volume>(<issue>6</issue>):<fpage>300060520925660</fpage>. doi: <pub-id pub-id-type="doi">10.1177/0300060520925660</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Manna</surname> <given-names>M</given-names>
</name>
<name>
<surname>Orlando</surname> <given-names>V</given-names>
</name>
<name>
<surname>Prezzemolo</surname> <given-names>T</given-names>
</name>
<name>
<surname>Di Carlo</surname> <given-names>P</given-names>
</name>
<name>
<surname>Cascio</surname> <given-names>A</given-names>
</name>
<name>
<surname>Delogu</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Mycobacterium tuberculosisHLA-E-Restricted CD8 T Lymphocytes Efficiently Control and HIV-1 Coinfection</article-title>. <source>Am J Respir Cell Mol Biol</source> (<year>2020</year>) <volume>62</volume>(<issue>4</issue>):<page-range>430&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1165/rcmb.2019-0261OC</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Du</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhan</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>NLRC3 Negatively Regulates CD4+ T Cells and Impacts Protective Immunity During Mycobacterium Tuberculosis Infection</article-title>. <source>PloS Pathog</source> (<year>2018</year>) <volume>14</volume>(<issue>8</issue>):<elocation-id>e1007266</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1007266</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corominas</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cardona</surname> <given-names>V</given-names>
</name>
<name>
<surname>Gonzalez</surname> <given-names>L</given-names>
</name>
<name>
<surname>Cayl&#xe0;</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Rufi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Mestre</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>B-Lymphocytes and Co-Stimulatory Molecules in Mycobacterium Tuberculosis Infection</article-title>. <source>Int J Tuberc Lung Dis</source> (<year>2004</year>) <volume>8</volume>(<issue>1</issue>):<fpage>98</fpage>&#x2013;<lpage>105</lpage>. PMID: 14974752</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maglione</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>B Cells Moderate Inflammatory Progression and Enhance Bacterial Containment Upon Pulmonary Challenge With Mycobacterium Tuberculosis</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>11</issue>):<page-range>7222&#x2013;34</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.178.11.7222</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosio</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Gardner</surname> <given-names>D</given-names>
</name>
<name>
<surname>Elkins</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>Infection of B Cell-Deficient Mice With CDC 1551, a Clinical Isolate of Mycobacterium Tuberculosis: Delay in Dissemination and Development of Lung Pathology</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>164</volume>(<issue>12</issue>):<page-range>6417&#x2013;25</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.164.12.6417</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kathamuthu</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Moideen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Banurekha</surname> <given-names>VV</given-names>
</name>
<name>
<surname>Nair</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sridhar</surname> <given-names>R</given-names>
</name>
<name>
<surname>Baskaran</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Altered Circulating Levels of B Cell Growth Factors and Their Modulation Upon Anti-Tuberculosis Treatment in Pulmonary Tuberculosis and Tuberculous Lymphadenitis</article-title>. <source>PloS One</source> (<year>2018</year>) <volume>13</volume>(<issue>11</issue>):<elocation-id>e0207404</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0207404</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stochino</surname> <given-names>C</given-names>
</name>
<name>
<surname>Villa</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zucchi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Parravicini</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gori</surname> <given-names>A</given-names>
</name>
<name>
<surname>Raviglione</surname> <given-names>MC</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical Characteristics of COVID-19 and Active Tuberculosis Co-Infection in an Italian Reference Hospital</article-title>. <source>Eur Respir J</source> (<year>2020</year>) <volume>56</volume>(<issue>1</issue>):<fpage>2001708</fpage>. doi: <pub-id pub-id-type="doi">10.1183/13993003.01708-2020</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Motta</surname> <given-names>I</given-names>
</name>
<name>
<surname>Centis</surname> <given-names>R</given-names>
</name>
<name>
<surname>D'Ambrosio</surname> <given-names>L</given-names>
</name>
<name>
<surname>Garc&#xed;a-Garc&#xed;a</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Goletti</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gualano</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Tuberculosis, COVID-19 and Migrants: Preliminary Analysis of Deaths Occurring in 69 Patients From Two Cohorts</article-title>. <source>Pulmonology</source> (<year>2020</year>) <volume>26</volume>(<issue>4</issue>):<page-range>233&#x2013;40</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.pulmoe.2020.05.002</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>G</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gamber</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>COVID-19 in Tuberculosis Patients: A Report of Three Cases</article-title>. <source>J Med Virol</source> (<year>2020</year>) <volume>92</volume>(<issue>10</issue>):<page-range>1802&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jmv.25943</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyasaka</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Is BCG Vaccination Causally Related to Reduced COVID-19 Mortality</article-title>? <source>EMBO Mol Med</source> (<year>2020</year>) <volume>12</volume>(<issue>6</issue>):<elocation-id>e12661</elocation-id>. doi: <pub-id pub-id-type="doi">10.15252/emmm.202012661</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahu</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Lal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sahu</surname> <given-names>SA</given-names>
</name>
</person-group>. <article-title>India Fights Back: COVID-19 Pandemic</article-title>. <source>Heart Lung</source> (<year>2020</year>) <volume>49</volume>(<issue>5</issue>):<page-range>446&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.hrtlng.2020.04.014</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Escobar</surname> <given-names>LE</given-names>
</name>
<name>
<surname>Molina-Cruz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Barillas-Mury</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>BCG Vaccine Protection From Severe Coronavirus Disease 2019 (COVID-19)</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2020</year>) <volume>117</volume>(<issue>30</issue>):<page-range>17720&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2008410117</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>M</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2021</year>) <volume>11</volume>:<elocation-id>766922</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2021.766922</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barreda</surname> <given-names>D</given-names>
</name>
<name>
<surname>Santiago</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rodr&#xed;guez</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rodr&#xed;guez</surname> <given-names>J</given-names>
</name>
<name>
<surname>Casasnovas</surname> <given-names>J</given-names>
</name>
<name>
<surname>M&#xe9;rida</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells</article-title>. <source>Cells</source> (<year>2021</year>) <volume>10</volume>(<issue>12</issue>):<fpage>3279</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10123279</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>YG</given-names>
</name>
<name>
<surname>Tam</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Transcriptional Profiling and Machine Learning Unveil a Concordant Biosignature of Type I Interferon-Inducible Host Response Across Nasal Swab and Pulmonary Tissue for COVID-19 Diagnosis</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>733171</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.733171</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Y</given-names>
</name>
<name>
<surname>and Wu</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>An Integrative Multiomics Analysis Identifies Putative Causal Genes for COVID-19 Severity</article-title>. <source>Genet Med</source> (<year>2021</year>) <volume>23</volume>(<issue>11</issue>):<page-range>2076&#x2013;86</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41436-021-01243-5</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Julian</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kazakoff</surname> <given-names>M</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jaynes</surname> <given-names>J</given-names>
</name>
<name>
<surname>Willis</surname> <given-names>M</given-names>
</name>
<name>
<surname>and Yates</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Chemokine-Based Therapeutics for the Treatment of Inflammatory and Fibrotic Convergent Pathways in COVID-19</article-title>. <source>Curr pathobiology Rep</source> (<year>2021</year>) <volume>p</volume>:<fpage>1</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40139-021-00226-0</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uranga-Murillo</surname> <given-names>I</given-names>
</name>
<name>
<surname>Morte</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hidalgo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pesini</surname> <given-names>C</given-names>
</name>
<name>
<surname>Garc&#xed;a-Mulero</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sierra</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Integrated Analysis of Circulating Immune Cellular and Soluble Mediators Reveals Specific COVID19 Signatures at Hospital Admission With Utility for Prediction of Clinical Outcomes</article-title>. <source>Theranostics</source> (<year>2022</year>) <volume>12</volume>(<issue>1</issue>):<fpage>290</fpage>&#x2013;<lpage>306</lpage>. doi: <pub-id pub-id-type="doi">10.7150/thno.63463</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Integrative Multi-Omics Landscape of Non-Structural Protein 3 of Severe Acute Respiratory Syndrome Coronaviruses</article-title>. <source>Genomics Proteomics Bioinf</source> (<year>2021</year>) <volume>21</volume>:<page-range>00241&#x2013;2</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.gpb.2021.09.007</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rofeal</surname> <given-names>M</given-names>
</name>
<name>
<surname>El-Malek</surname> <given-names>FA</given-names>
</name>
</person-group>. <article-title>Ribosomal Proteins as a Possible Tool for Blocking SARS-COV 2 Virus Replication for a Potential Prospective Treatment</article-title>. <source>Med Hypotheses</source> (<year>2020</year>) <volume>143</volume>:<fpage>109904</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mehy.2020.109904</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Jiao</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>and Xing</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Quantitative Proteomic Analysis of Trachea in Fatting Pig Exposed to Ammonia</article-title>. <source>J Proteomics</source> (<year>2021</year>) <volume>247</volume>:<fpage>104330</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jprot.2021.104330</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ying</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Correlation Between MBL2/CD14/TNF-&#x3b1; Gene Polymorphisms and Susceptibility to Spinal Tuberculosis in Chinese Population</article-title>. <source>Bioscience Rep</source> (<year>2018</year>) <volume>38</volume>(<issue>1</issue>):<fpage>BSR20171140</fpage>. doi: <pub-id pub-id-type="doi">10.1042/BSR20171140</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Barnitz</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Snow</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bidere</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Ribosomal Protein S3: A KH Domain Subunit in NF-kappaB Complexes That Mediates Selective Gene Regulation</article-title>. <source>Cell</source> (<year>2007</year>) <volume>131</volume>(<issue>5</issue>):<page-range>927&#x2013;39</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2007.10.009</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>HW</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>HN</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>ZW</given-names>
</name>
<etal/>
</person-group>. <article-title>Systematic Identification of Mycobacterium Tuberculosis Effectors Reveals That BfrB Suppresses Innate Immunity</article-title>. <source>Mol Cell Proteomics</source> (<year>2017</year>) <volume>16</volume>(<issue>12</issue>):<page-range>2243&#x2013;53</page-range>. doi: <pub-id pub-id-type="doi">10.1074/mcp.RA117.000296</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prisic</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Dow</surname> <given-names>A</given-names>
</name>
<name>
<surname>Barnaby</surname> <given-names>O</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Lonzanida</surname> <given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Zinc Regulates a Switch Between Primary and Alternative S18 Ribosomal Proteins in Mycobacterium Tuberculosis</article-title>. <source>Mol Microbiol</source> (<year>2015</year>) <volume>97</volume>(<issue>2</issue>):<page-range>263&#x2013;80</page-range>. doi: <pub-id pub-id-type="doi">10.1111/mmi.13022</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisco</surname> <given-names>G</given-names>
</name>
<name>
<surname>De Tullio</surname> <given-names>A</given-names>
</name>
<name>
<surname>Stragapede</surname> <given-names>A</given-names>
</name>
<name>
<surname>Solimando</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Albanese</surname> <given-names>F</given-names>
</name>
<name>
<surname>Capobianco</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>COVID-19 and the Endocrine System: A Comprehensive Review on the Theme</article-title>. <source>J Clin Med</source> (<year>2021</year>) <volume>10</volume>(<issue>13</issue>):<fpage>2920</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm10132920</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izawa</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>[HISTOLOGICAL ANALYSIS OF BONE DESTRUCTION IN SPINAL TUBERCULOSIS]</article-title>. <source>Kekkaku</source> (<year>2015</year>) <volume>90</volume>(<issue>3</issue>):<page-range>415&#x2013;20</page-range>. PMID: 26477111</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoshino</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hanada</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yamada</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mii</surname> <given-names>S</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mitarai</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Mycobacterium Tuberculosis Escapes From the Phagosomes of Infected Human Osteoclasts Reprograms Osteoclast Development via Dysregulation of Cytokines and Chemokines</article-title>. <source>Pathog Dis</source> (<year>2014</year>) <volume>70</volume>(<issue>1</issue>):<fpage>28</fpage>&#x2013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1111/2049-632X.12082</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Udagawa</surname> <given-names>N</given-names>
</name>
<name>
<surname>Koide</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nakamichi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yamashita</surname> <given-names>T</given-names>
</name>
<name>
<surname>Uehara</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Osteoclast Differentiation by RANKL and OPG Signaling Pathways</article-title>. <source>J Bone Miner Metab</source> (<year>2021</year>) <volume>39</volume>(<issue>1</issue>):<fpage>19</fpage>&#x2013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00774-020-01162-6</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ono</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hayashi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sasaki</surname> <given-names>F</given-names>
</name>
<name>
<surname>Nakashima</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>RANKL Biology: Bone Metabolism, the Immune System, and Beyond</article-title>. <source>Inflammation Regener</source> (<year>2020</year>) <volume>40</volume>:<fpage>2</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s41232-019-0111-3</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>